Home Business Life Science

Subscribe Now

Life Science

Altos Labs launches Cambridge Institute of Science with cellular rejuvenation mission — Altos Labs launches Cambridge Institute of Science with cellular rejuvenation mission

Granta Park company arrives with mystery investors rumoured to include Jeff Bezos

Microbiotica ready to cross therapeutic threshold with clinical trials milestone

Microbiotica ready to cross therapeutic threshold with clinical trials milestone

Microbiotica ready to cross therapeutic threshold with clinical trials milestone

Cambridge microbiome specialist prepares MB097 and MB310 for human testing

First patient dose as trial of Bicycle Therapeutics’ anti-tumour molecule steps up

First patient dose as trial of Bicycle Therapeutics’ anti-tumour molecule steps up

First patient dose as trial of Bicycle Therapeutics’ anti-tumour molecule steps up

Company says it is pleased with early signs.

Axol Bioscience offers IPSC-derived heart cells for use in drug testing

Axol Bioscience offers IPSC-derived heart cells for use in drug testing

Axol Bioscience offers IPSC-derived heart cells for use in drug testing

They can be used to test cardiotoxicity in a dish.

‘Trojan horse’ diabetes drug that could halt disease progression undergoes clinical trials at Addenbrooke’s

‘Trojan horse’ diabetes drug that could halt disease progression undergoes clinical trials at Addenbrooke’s

‘Trojan horse’ diabetes drug that could halt disease progression undergoes clinical trials at Addenbrooke’s

It ‘flips the culprit immune cells into destroying themselves’, explains Prof Mark Evans.

Tripling size of Wellcome Genome Campus will benefit global science, says Prof Sir Mike Stratton

Tripling size of Wellcome Genome Campus will benefit global science, says Prof Sir Mike Stratton

Tripling size of Wellcome Genome Campus will benefit global science, says Prof Sir Mike Stratton

The cancer genetics pioneer discusses the future of the campus and the importance of biodata.

Cambridge start-up Enhanc3D Genomics wins Johnson & Johnson support for human 3D genome technology

Cambridge start-up Enhanc3D Genomics wins Johnson & Johnson support for human 3D genome technology

Cambridge start-up Enhanc3D Genomics wins Johnson & Johnson support for human 3D genome technology

Platform could aid precision medicine.

‘I had no confidence of success’ says Wellcome Sanger Institute director and cancer genetics pioneer Prof Sir Mike Stratton

‘I had no confidence of success’ says Wellcome Sanger Institute director and cancer genetics pioneer Prof Sir Mike Stratton

‘I had no confidence of success’ says Wellcome Sanger Institute director and cancer genetics pioneer Prof Sir Mike Stratton

An exclusive in-depth interview with the winner of our inaugural Lifetime Achievement Award.

NRG Therapeutics’ £2.68m award will help fund new hope against Parkinson’s disease

NRG Therapeutics’ £2.68m award will help fund new hope against Parkinson’s disease

NRG Therapeutics’ £2.68m award will help fund new hope against Parkinson’s disease

It will fund the clinical development of its brain-penetrating small molecule inhibitors.

AstraZeneca CEO Pascal Soriot is knighted after leadership during pandemic

AstraZeneca CEO Pascal Soriot is knighted after leadership during pandemic

AstraZeneca CEO Pascal Soriot is knighted after leadership during pandemic

He is honoured in the Queen’s Jubilee Birthday Honours 2022.

Bicycle Therapeutics opens new headquarters on Granta Park

Bicycle Therapeutics opens new headquarters on Granta Park

Bicycle Therapeutics opens new headquarters on Granta Park

Sir Greg Winter among speakers as Portway Building premises team looks to accelerate development of synthesised medicines

In pictures: King and queen of Sweden tour AstraZeneca’s Discovery Centre on visit to Cambridge

In pictures: King and queen of Sweden tour AstraZeneca’s Discovery Centre on visit to Cambridge

In pictures: King and queen of Sweden tour AstraZeneca’s Discovery Centre on visit to Cambridge

King Carl XVI Gustaf and Queen Silvia were given an insight into the company’s cutting-edge R&D technology.

Avacta completes move away from Whittlesford to White City

Avacta completes move away from Whittlesford to White City

Avacta completes move away from Whittlesford to White City

The company has brought its R&D teams together in London.

AstraZeneca revenues rise 60% to $11bn in first quarter as it unveils plans for new Alexion headquarters

AstraZeneca revenues rise 60% to $11bn in first quarter as it unveils plans for new Alexion headquarters

AstraZeneca revenues rise 60% to $11bn in first quarter as it unveils plans for new Alexion headquarters

Meanwhile, it expects sales of its Covid-19 vaccine to decline in 2022.

Dengue threat to be tackled using AI-powered drug discovery as BenevolentAI teams up with DNDi

Dengue threat to be tackled using AI-powered drug discovery as BenevolentAI teams up with DNDi

Dengue threat to be tackled using AI-powered drug discovery as BenevolentAI teams up with DNDi

There are an estimated 390 million infections each year.

Spanish medical imaging specialist Quibim heads to Cambridge after support

Spanish medical imaging specialist Quibim heads to Cambridge after support

Spanish medical imaging specialist Quibim heads to Cambridge after support

Growth Works and Eastern AHSN helped the company as it scales.

Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

The Cambridge Science Park company is also working with Roche Diagnostics on a liver cancer pilot study.

Avacta achieves AffyXell joint venture milestone, triggering increased equity stake

Avacta achieves AffyXell joint venture milestone, triggering increased equity stake

Avacta achieves AffyXell joint venture milestone, triggering increased equity stake

It has developed and characterised Affimer proteins against the first target for AffyXell.

How Adrestia Therapeutics is pioneering synthetic rescue

How Adrestia Therapeutics is pioneering synthetic rescue

How Adrestia Therapeutics is pioneering synthetic rescue

An interview with Prof Steve Jackson and CEO Robert Johnson

Axol Bioscience raises further £3.2m to extend iPSC products for drug discovery market

Axol Bioscience raises further £3.2m to extend iPSC products for drug discovery market

Axol Bioscience raises further £3.2m to extend iPSC products for drug discovery market

It extends the total raised to £7m.

BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies

BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies

BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies

The Cambridge biotech wants to ‘drive a revolution in biology’.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More